Przejdź do zawartości
Merck

S1438

Sigma-Aldrich

Sulindac sulfone

≥94% (HPLC), (solid or powder)

Synonim(y):

(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic acid

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C20H17FO4S
Numer CAS:
Masa cząsteczkowa:
372.41
Numer MDL:
Kod UNSPSC:
51111800
Identyfikator substancji w PubChem:
NACRES:
NA.77

Poziom jakości

Próba

≥94% (HPLC)

Postać

(solid or powder)

kolor

, Light Yellow to Dark Yellow

rozpuszczalność

DMSO: >25 mg/mL
ethanol: 3 mg/mL (warm)
acetone: 5 mg (plus 0.1 ml)

inicjator

Merck & Co., Inc., Kenilworth, NJ, U.S.

ciąg SMILES

CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c3ccc(cc3)S(C)(=O)=O

InChI

1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+

Klucz InChI

MVGSNCBCUWPVDA-RQZCQDPDSA-N

Zastosowanie

Human endothelial cells, HMEC-1 were treated with Sulindac sulfone and the effect on cell survival was studied by MTT assay.

Działania biochem./fizjol.

Sulindac sulfone is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells1,2 and reduces tumor burden in adenomatous polyposis patients.3
Metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. Inhibits the development and induces regression of premalignant adenomatous polyps.

Cechy i korzyści

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Uwaga dotycząca przygotowania

Sulindac sulfone yields clear, light yellow to dark yellow solution in acetone at 50 mg/ml.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Środki ochrony indywidualnej

Eyeshields, Gloves, type N95 (US)


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Steven Attia et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3(9), 1018-1025 (2008-09-02)
Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC. Chemotherapy-naive
Ramaswamy Govindan et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 4(2), 220-226 (2009-01-31)
To assess the efficacy and toxicity of carboplatin, etoposide, and exisulind as initial therapy for extensive stage small cell lung cancer. The Cancer and Leukemia Group B conducted a phase II study of carboplatin (area under the curve 6) day
Jun-Yang Liou et al.
Cancer research, 67(7), 3185-3191 (2007-04-06)
To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of sulindac on 14-3-3epsilon protein expression in colorectal cancer cells. Sulindac sulfide inhibited 14-3-3epsilon proteins in HT-29 and DLD-1 cells
Glen J Weiss et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2(10), 933-938 (2007-10-03)
This multicenter, phase II clinical trial was conducted to evaluate the activity of the combination of docetaxel and exisulind in advanced non-small cell lung cancer (NSCLC) patients who failed a prior platinum-containing regimen. Patients with measurable disease and adequate organ
Nis Giladi et al.
Expert opinion on investigational drugs, 19 Suppl 1, S117-S124 (2010-04-14)
The use of sulindac sulfone (SFN) for colorectal cancer (CRC) therapy is limited due to its toxicity. The present study was carried out to examine whether curcumin, a novel chemopreventive agent, can potentiate the effects of low dosages of SFN

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej